ArticleChemical informatics (Wilmington, Del.)2017
High-Throughput Screening Assay Datasets from the PubChem Database.
Article in Chemical informatics (Wilmington, Del.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Article
- Rapid and energy-efficient ultra-large library screening for drug discovery on a SpiNNaker2 neuromorphic chip.Communications chemistry · 2026Article
- RosettaAMRLD: A Reaction-Driven Approach for Structure-Based Drug Design from Combinatorial Libraries with Monte Carlo Metropolis Algorithms.Journal of chemical information and modeling · 2025Article
- Crossover operators for molecular graphs with an application to virtual drug screening.Journal of cheminformatics · 2025Article
- Advancements in Ligand-Based Virtual Screening through the Synergistic Integration of Graph Neural Networks and Expert-Crafted Descriptors.Journal of chemical information and modeling · 2025Article
- Role of artificial intelligence in revolutionizing drug discovery.Fundamental research · 2025Review
- Article
- A review of deep learning methods for ligand based drug virtual screening.Fundamental research · 2024Review
- Machine Learning Assisted Hit Prioritization for High Throughput Screening in Drug Discovery.ACS central science · 2024Article
- Microfluidics in High-Throughput Drug Screening: Organ-on-a-Chip andBiosensors · 2024Review
- Material basis and molecular mechanisms of Chaihuang Qingyi Huoxue Granule in the treatment of acute pancreatitis based on network pharmacology and molecular docking-based strategy.Frontiers in immunology · 2024Article
- Drug Design-Past, Present, Future.Molecules (Basel, Switzerland) · 2022Review
- Assisting Multitargeted Ligand Affinity Prediction of Receptor Tyrosine Kinases Associated Nonsmall Cell Lung Cancer Treatment with Multitasking Principal Neighborhood Aggregation.Molecules (Basel, Switzerland) · 2022Article
- Deep Learning in Virtual Screening: Recent Applications and Developments.International journal of molecular sciences · 2021Review
- General Purpose Structure-Based Drug Discovery Neural Network Score Functions with Human-Interpretable Pharmacophore Maps.Journal of chemical information and modeling · 2021Article
- BCL::Mol2D-a robust atom environment descriptor for QSAR modeling and lead optimization.Journal of computer-aided molecular design · 2019Article
- The Distribution of Standard Deviations Applied to High Throughput Screening.Scientific reports · 2019Article
- Review
- Evaluation of Health Risk Level of Hand-Arm and Whole-Body Vibrations on the Technical Operators and Equipment in a Tobacco-Producing Company in Nigeria.Journal of healthcare engineering · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Availability of high-throughput screening (HTS) data in the public domain offers great potential to foster development of ligand-based computer-aided drug discovery (LB-CADD) methods crucial for drug discovery efforts in academia and industry. LB-CADD method development depends on high-quality HTS assay data, i.e., datasets that contain both active and inactive compounds. These active compounds are hits from primary screens that have been tested in concentration-response experiments and where the target-specificity of the hits has been validated through suitable secondary screening experiments. Publicly available HTS repositories such as PubChem often provide such data in a convoluted way: compounds that are classified as inactive need to be extracted from the primary screening record. However, compounds classified as active in the primary screening record are not suitable as a set of active compounds for LB-CADD experiments due to high false-positive rate. A suitable set of actives can be derived by carefully analysing results in often up to five or more assays that are used to confirm and classify the activity of compounds. These assays, in part, build on each other. However, often not all hit compounds from the previous screen have been tested. Sometimes a compound can be classified as 'active', though its meaning is 'inactive' on the target of interest as it is 'active' on a different target protein. Here, a curation process of hierarchically related confirmatory screens is illustrated based on two specifically chosen protein use-cases. The subsequent re-upload procedure into PubChem is described for the findings of those two scenarios. Further, we provide nine publicly accessible high quality datasets for future LB-CADD method development that provide a common baseline for comparison of future methods to the scientific community. We also provide a protocol researchers can follow to upload additional datasets for benchmarking.
Indexed as
Identifiers
29795804PMC5962024What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.